 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Tuesday, October 31, 2006
Biogen Idec Upgraded On Tysabri Outlook - Forbes.com
Bear Stearns upgraded shares of Biogen Idec to "peer perform" from "underperform" on Monday and said the prospects for multiple sclerosis drug Tysabri look brighter,..."The roll-out of Tysabri might be faster than we had originally expected," wrote Bear Stearns analyst Mark Schoenebaum in a research report.
The analyst based the promotion on new data released last week by Biogen Idec (nasdaq: BIIB - news - people )'s marketing partner Elan (nyse: ELN - news - people ), which showed that 4,500 patients have already enrolled in the Touch program, a strict safety monitoring system mandated by federal health regulators.MORE
Bear Stearns upgraded shares of Biogen Idec to "peer perform" from "underperform" on Monday and said the prospects for multiple sclerosis drug Tysabri look brighter,..."The roll-out of Tysabri might be faster than we had originally expected," wrote Bear Stearns analyst Mark Schoenebaum in a research report.
The analyst based the promotion on new data released last week by Biogen Idec (nasdaq: BIIB - news - people )'s marketing partner Elan (nyse: ELN - news - people ), which showed that 4,500 patients have already enrolled in the Touch program, a strict safety monitoring system mandated by federal health regulators.MORE